Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIME Study
NCT02707042Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Mar 2017
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of amoxicillin and azithromycin (3 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Antibiotic-induced perturbation of the microbiome and its metabolic and immunologic effects. Started Mar 2017; status: completed.
02
Drugs
amoxicillinazithromycin
Beyond the preview
Go deeper on NCT02707042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02707042.